Novo Nordisk Open to Direct New York Listing

Novo Nordisk CEO Mike Doustdar is open to a direct New York Stock Exchange listing, replacing American depositary receipts for United States investors. The move comes as the Denmark-based drugmaker faces intense competition in the weight-loss market. The United States accounts for over half of Novo's revenue, driven by its diabetes and obesity treatments.